OGAP® Discovery Platform
OBT’s proprietary platform, OGAP®, is the world’s largest cancer specific membrane protein library, directly measuring plasma membrane protein expression in patient tumors.
OGAP is used to identify novel, highly tumor specific antigens for novel first-in-class ADC, Bispecific T-cell Engager (BiTE ®) and Chimeric Antigen Receptor (CAR) targets. OGAP provides deep coverage of cancer and healthy tissues’ cell surface proteome using proteomics and has the ability to successfully identify and characterize known, existing targets being developed by many companies, and importantly identify new, novel and previously unknown cell-surface cancer targets.
The platform has been leveraged in external partnerships with leaders in the oncology space, including Boehringer Ingelheim and Kite.
OGAP is used to identify novel, highly tumor specific antigens for novel first-in-class ADC, Bispecific T-cell Engager (BiTE ®) and Chimeric Antigen Receptor (CAR) targets. OGAP provides deep coverage of cancer and healthy tissues’ cell surface proteome using proteomics and has the ability to successfully identify and characterize known, existing targets being developed by many companies, and importantly identify new, novel and previously unknown cell-surface cancer targets.
The platform has been leveraged in external partnerships with leaders in the oncology space, including Boehringer Ingelheim and Kite.
